WHAT WE'RE READING

989  A Sampling of Highlights from the Literature

CANCER IMMUNOLOGY AT THE CROSSROADS

Jonathan A. Trujillo, Randy F. Sweis, Riyue Bao, and Jason J. Luke

CANCER IMMUNOLOGY MINIATURES

1001  Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Jeremy Lewin, Scott Davidson, Nathaniel D. Anderson, Beatrice Y. Lau, Jacalyn Kelly, Uri Tabori, Samer Salah, Marcus O. Butler, Kyaw L. Aung, Adam Shljen, Brendan C. Dickson, and Albinuri R. Abdur Razak

1008  Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies
Jing Chang, Haiyong Peng, Brian C. Shaffer, Siva Subramanian Baskar, Ina C. Wecken, Matthew G. Cyr, Gustavo J. Martinez, Jo Soden, Jim Freeth, Adrian Wiestner, and Christoph Rader

1014  IL-35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Bhalchandra Mirlekar, Daniel Michaud, Ryan Searcy, Kevin Greene, and Yuliya Pylayeva-Gupta
IL-35 was identified as a major regulator of T cell–mediated antitumor responses in pancreatic ductal adenocarcinoma. IL-35 deficiency in vivo allowed for increased effector T-cell infiltration into tumors and improved the efficacy of anti–PD-1 therapy.

1025  Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability
Jeremy Lewin, Scott Davidson, Nathaniel D. Anderson, Beatrice Y. Lau, Jacalyn Kelly, Uri Tabori, Samer Salah, Marcus O. Butler, Kyaw L. Aung, Adam Shljen, Brendan C. Dickson, and Albinuri R. Abdur Razak
Two patients with ASPS responded to immune checkpoint inhibition. Genomic analysis of a larger group of patients demonstrated molecular mismatch repair deficiency signatures in 71% of patients. Immune checkpoint blockade may be a useful therapy for ASPS.

1039  Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Melanoma patients presenting with brain metastases have been mostly excluded from treatment trials. A large-scale analysis of these patients from a national cohort revealed that after immune checkpoint blockade, median and 4-year overall survival were significantly improved.

1046  Circulating Tumor Microparticles Promote Lung Metastasis by Reprogramming Inflammatory and Mechanical Niches via a Macrophage-Dependent Pathway
Hua-Lin Zhang, Yuandong Yu, Li Zhou, Jingwei Ma, Ke Tang, Pingwei Xu, Tianzhen Ji, Xiaoyu Liang, Jiali Lv, Wenguang Dong, Tianzhen Zhang, Degao Chen, Jing Xie, Yuying Liu, and Bo Huang
Lung macrophages are induced by tumor-derived microparticles to drive development of metastasis via mediators that promote immune, inflammatory, and mechanical reprogramming of the microenvironment. Elucidation of this pathway has implications for therapeutic prevention or treatment of lung metastasis.
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1057</td>
<td>Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8⁺ T Cells</td>
<td>Jingwei Ma, Keke Wei, Huaifeng Zhang, Ke Tang, Fei Li, Tianchen Zhang, Junwei Liu, Pingwei Xu, Yuandong Yu, Weiwei Sun, Liyan Zhu, Jie Chen, Li Zhou, Xiaoyu Liang, Jiadi Lv, Roland Fiskesund, Yuying Liu, and Bo Huang</td>
</tr>
<tr>
<td>1082</td>
<td>RO8(+) Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells</td>
<td>Angelamaria Rizzo, Martina Di Giovangiulio, Carmine Stolfi, Eleonora Franz, Hans-Joerg Fehling, Rita Casetti, Ezio Giorda, Alfredo Colantoni, Angela Ortenzi, Massimo Rugge, Claudia Mescoli, Giovanni Monteleone, and Massimo C. Fantini</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

Although immunotherapy has shown success in treating a variety of cancers, patients with pancreatic ductal adenocarcinoma (PDA) remain unresponsive to treatment, and the lack of efficient antitumor responses is not yet well understood. Mirlekar et al. establish IL35 as a driver of PDA tumor growth via suppression of T-cell-mediated responses. Comparison of mice with and without this cytokine show that IL35’s absence significantly reduces pancreatic tumor growth, increases tumor infiltration by CD8⁺ T cells, and improves anti-PD-1 efficacy. Thus, IL35 is a cytokine that may be targeted to improve antitumor responses in PDA, including responses to PD-1 blockade. Read more in this issue starting on page 1014. Original immunofluorescence image of human PDA from Supplementary Fig. 5Ac. Artwork by Lewis Long.